Background
Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections.• Diabetic retinopathy., PMID:22455417• Novel Target for Limiting VEGF-A (Vascular Endothelial Growth Factor A)-Induced Vascular Permeability., PMID:36004641• Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis., PMID:32654325• Interleukin-37, vascular endothelial growth factor A, and transforming growth factor-β1: promising biomarkers in primary immune thrombocytopenia., PMID:35815383• [Research progress of vascular endothelial growth factor-A and its isoforms in kidney disease]., PMID:35199126• Life and Death of Podocytes: Not Only a Matter of Vascular Endothelial Growth Factor., PMID:26930245• Preface., PMID:30612609• Monoclonal antibodies neutralizing alpha-hemolysin, bicomponent leukocidins, and clumping factor A protected againstStaphylococcus aureus-induced acute circulatory failure in a mechanically ventilated rabbit model of hyperdynamic septic shock., PMID:37781371• Diabetic retinopathy., PMID:22784133• Diabetic retinopathy., PMID:22784134